COMPASS Pathways plc (CMPS): Net earnings per share for the last 12 months

The change in TTM net income per share reported by the GURU.Markets portal, where the value -3.50 corresponds to the current metric, complements the COMPASS Pathways plc (CMPS) ecosystem, which links digital software with psychedelic treatment. COMPASS Pathways plc (CMPS) is based on the principles of bioethics and sustainable production. Business stability is ensured by patents for depression therapy, which create a significant barrier to entry for competitors.

CMPS (COMPASS Corp) Net earnings per share for the last 12 months history from 07/04/2022 to 11/10/2026

Analytical breakdowns and data insights for company COMPASS Pathways PLC (CMPS)

- current quotes and average value forecast:

Price Chart COMPASS Pathways plc|CMPS - Analyst Median Target

- stock exchange capitalization data:

Market Valuation COMPASS Pathways plc|CMPS - Total Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share COMPASS Pathways|CMPS - Company Net Assets|Market Capitalization to Book Value Ratio compasspathways.com|CMPS - Aggregate Asset Value

- debt and liquidity details:

- net income and valuation multiples indicators:

CMPS - Profit After Tax|Projected Future Earnings COMPASS Pathways plc|CMPS - P/E Multiple|Future Price to Earnings COMPASS Pathways|CMPS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COMPASS Pathways plc|CMPS - Operating income before deduction of amortization|Net earnings per share for the last 12 months COMPASS Pathways|CMPS - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months compasspathways.com|CMPS - Earnings per share trend in current year|Earnings growth forecast for next year COMPASS Pathways plc

Initial company analysis:CMPS - COMPASS Pathways plc

Mass-produced product of COMPASS Pathways PLC

TTM net income per share measures the aggregate net income of the enterprise over the last four quarters, allocated per security to evaluate profit generation efficiency. An analysis of the fundamental TTM net income per share for COMPASS Pathways plc (CMPS) reflects the financial burden of the late-stage clinical trial phase, where the metric's volatility serves as an indicator of the management structure's adaptation to regulatory requirements.

Main competitors

ALKS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters avadel.com AVDL|ATAI (atai Life Sciences) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months GH Research plc (GHRS)|MNMD (MindMed Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months LB Corp (LBRX)|Net earnings per share (EPS TTM) DRUG|VNDA (vandapharma.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Cybin CYBN|Alto Neuroscience Inc (ANRO) - Net earnings per one share for the last twelve months|NRx Pharma - Net earnings per share (EPS TTM)|Cingulate Inc. (CING) - Net earnings per share for the last 12 months|Silo Pharma, Inc. (SILO) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months China Pharma Holdings, Inc. (CPHI)|Earnings per share for the last twelve months Clearmind Medicine|Net earnings per share for the last 12 months Psyence Biomedical Ltd (PBM)|Earnings per share for the last twelve months Clearmind Medicine (SPRC)|SEEL: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) VRPX (Virpax Pharmaceuticals, Inc.)|Net earnings per share (EPS TTM) karunatx.com KRTX